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Restoration of normal 
embryogenesis by mitochondrial 
supplementation in pig oocytes 
exhibiting mitochondrial DNA 
deficiency
Gael L. M. Cagnone1,2,*, Te-Sha Tsai1,2,*, Yogeshwar Makanji1,2, Pamela Matthews1,2, 
Jodee Gould2,3, Michael S. Bonkowski4, Kirstin D. Elgass5, Ashley S. A. Wong6, Lindsay E. Wu6, 
Matthew McKenzie1,2, David A. Sinclair4 & Justin C. St. John1,2
An increasing number of women fail to achieve pregnancy due to either failed fertilization or embryo 
arrest during preimplantation development. This often results from decreased oocyte quality. Indeed, 
reduced mitochondrial DNA copy number (mitochondrial DNA deficiency) may disrupt oocyte quality 
in some women. To overcome mitochondrial DNA deficiency, whilst maintaining genetic identity, we 
supplemented pig oocytes selected for mitochondrial DNA deficiency, reduced cytoplasmic maturation 
and lower developmental competence, with autologous populations of mitochondrial isolate at 
fertilization. Supplementation increased development to blastocyst, the final stage of preimplantation 
development, and promoted mitochondrial DNA replication prior to embryonic genome activation 
in mitochondrial DNA deficient oocytes but not in oocytes with normal levels of mitochondrial DNA. 
Blastocysts exhibited transcriptome profiles more closely resembling those of blastocysts from 
developmentally competent oocytes. Furthermore, mitochondrial supplementation reduced gene 
expression patterns associated with metabolic disorders that were identified in blastocysts from 
mitochondrial DNA deficient oocytes. These results demonstrate the importance of the oocyte’s 
mitochondrial DNA investment in fertilization outcome and subsequent embryo development to 
mitochondrial DNA deficient oocytes.
Mitochondrial DNA (mtDNA) is a double-stranded circular genome that is approximately 16.6 kb in size and 
is located in the mitochondrial matrix1. It encodes 13 of the 80+ subunits of the electron transfer chain (ETC), 
which generates the vast majority of cellular ATP through oxidative phosphorylation (OXPHOS)2,3. The remain-
ing OXPHOS subunits are encoded by the chromosomal genome. The mitochondrial genome also encodes 
22 tRNAs and 2 rRNAs and has one non-coding region, the D-Loop, which is the site of interaction for the 
nuclear-encoded transcription and replication factors that translocate to the mitochondrion to first drive mtDNA 
transcription then replication4. Cells possess multiple copies of mtDNA, which are inherited from the population 
present in the oocyte at fertilization and passed from generation to generation through the female germline5.
There are a number of mtDNA disorders6, which include mtDNA deficiency syndromes that manifest in 
somatic tissues and organs and primarily affect cells that are highly dependent on OXPHOS for the generation 
of ATP6. Maturing mammalian oocytes and developing embryos are not highly dependent on OXPHOS. Their 
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mitochondria are structurally and functionally quiescent, and they likely derive most of their energy through 
alternative pathways, such as the adenosine salvage pathway7. They are also involved in a number of cellular 
functions including the sequestration and release of intracellular calcium. Furthermore, women harboring severe 
mtDNA mutations retain the capacity to be fertile8 hence the persistence of mild and severe forms of mtDNA 
disease6.
Whilst experimental reduction of mtDNA copy number does not impair preimplantation embryo develop-
ment in mice9, mtDNA depletion during pig oocyte in vitro maturation results in fertilisation failure or arrest 
during preimplantation development10. In addition, mtDNA deficiency appears to affect maturing pig oocytes 
resulting in their failure to complete nuclear and cytoplasmic maturation, which renders them developmentally 
incompetent10,11. Furthermore, human oocytes with low mtDNA copy number frequently fail to fertilise or arrest 
during preimplantation development12–17. To this extent, the amount of mtDNA present in the oocyte at fertilisa-
tion is likely to be an investment in subsequent developmental events. For example, during pig oocyte maturation, 
replication of mtDNA establishes a minimum investment of ~120 000 copies in oocytes that have the capacity to 
be fertilised10,11,18–20. This investment ensures that sufficient mtDNA is available during organogenesis so that each 
mature cell type has sufficient mtDNA copy number to meet its required metabolic demands, in a cell specific 
manner. This investment is important, as there is one brief mtDNA replication event that occurs between fertilis-
ation and the 2-cell stage. However, mtDNA replication does not then occur during preimplantation development 
until the blastocyst stage, and then not again in embryonic cells until post-gastrulation10,18–21.
Supplementing oocytes with mitochondria is a strategy to overcome mtDNA deficiency and enhance devel-
opmental competence. Indeed, supplementation of mtDNA deficient oocytes with autologous populations of 
mitochondrial isolate can enhance fertilisation outcome, reinforcing the relationship between mtDNA copy num-
ber and oocyte development11. Moreover, autologous supplementation would prevent the transmission of two 
populations of mtDNA, known as heteroplasmy, that arose following the transfer of donor cytoplasm into oocytes 
of women with repeated embryonic development failure22 and led to the associated developmental disorders that 
impact on offspring health and survival23,24.
Oocytes can be selected by staining with Brilliant Cresyl Blue (BCB), a non-toxic dye that is reduced to a color-
less compound by glucose-6-phosphate dehydrogenase (G6PD)25. As G6PD shows progressive down-regulation 
during oocyte growth, developmentally competent oocytes stain blue (BCB+ ) whilst developmentally incompe-
tent oocytes are colorless (BCB−)25. To this extent, BCB staining has been used in various mammalian species 
to assess developmental competence25,26. In addition, pig BCB+ oocytes contain significantly higher levels of 
mtDNA copy number than BCB− oocytes, as part of their differential competence to fertilise10,11. Indeed, the pig 
is an excellent model of oocyte and embryo development as these are very similar to that of the human27,28. In 
addition, mtDNA replication and reduction events have been mapped in porcine oocytes and embryos10,11, which 
are very similar to human oocytes and embryos10,11,14.
By supplementing BCB− oocytes with autologous populations of mitochondrial isolate, we can rescue a sig-
nificant proportion of oocytes, which enables them to progress to blastocyst. The impact is immediate with 2-cell 
stage embryos possessing enhanced levels of mtDNA. By enhancing BCB− oocytes with mtDNA, gene expression 
patterns in blastocysts are more similar to embryos originating from developmentally competent rather than 
developmentally incompetent oocytes.
Results
Nuclear and cytoplasmic maturation in BCB+ and BCB− oocytes. In an ovary, typically 38.7% ± 2.1 
(mean ± SEM) oocytes stain negatively for BCB (BCB−). To validate the use of BCB staining as a differen-
tial marker of oocyte maturation for oocytes that had not been synchronised to the S-phase of the cell cycle10 
(Supplementary Fig. 1), aspirated BCB+ and BCB− oocytes were assessed for Metaphase II (MII; polar body 
extrusion) after 44 hr of in vitro maturation (IVM). Significantly more BCB+ oocytes (51.4%) developed to MII 
than BCB− oocytes (20.3%; P < 0.0001; Supplementary Table 1), whilst lysis was higher in the BCB− population 
(51.2%; P < 0.0001) (Supplementary Table 1).
Real-time PCR was performed on individual in vitro matured BCB+ and BCB− oocytes at 0, 22 and 44 hr 
post-isolation from ovaries. BCB+ oocytes had high copy number at 0 hr, which decreased significantly at 22 hr 
(P < 0.01) and returned to higher levels at 44 hr (Fig. 1a). This was the case for oocytes that reached and failed 
to reach MII. BCB− oocytes behaved in the opposite manner with lower copy number at 0 hr followed by an 
increase at 22 hr and a return to far lower levels at 44 hr (Fig. 1b), demonstrating their incapacity to mediate 
nucleo-cytoplasmic interactions. The few BCB− oocytes reaching MII had lower mtDNA copy number than 
immature oocytes at 44 hr. A direct comparison of MII BCB+ and BCB− oocytes at 44 hr showed that BCB− 
oocytes had significantly fewer copies of mtDNA (P < 0.01; Fig. 1c).
Furthermore, mitochondria isolated from BCB+ oocytes exhibited lower respiration rates than mitochon-
dria from BCB− oocytes when stimulated with succinate and ADP, but higher respiratory capacity when uncou-
pled with FCCP (Supplementary Fig. 2). BCB+ mitochondria were also in a more quiescent state than their 
BCB− counterparts. In addition, there were distinct profiles for the distribution and clustering of mitochondria 
in BCB+ and BCB− oocytes following staining with MitoTracker Deep Red (Supplementary Fig. 3). When cluster 
area, perimeter and circularity were chosen as parameters for characterization, there were significant differences 
between cluster area and perimeter for the two populations of oocytes.
Supplementation of BCB− oocytes with isolated mitochondria. Using cohorts of MII BCB+ and 
BCB− oocytes, we generated a series of blastocyst stage embryos through in vitro fertilisation (IVF), intracyto-
plasmic sperm injection (ICSI) and mitochondrial supplementation in combination with ICSI (mICSI) (Table 1). 
We generated a mitochondrial isolate from 5 to 10 BCB+ metaphase II oocytes for each ovary pair. The num-
ber of mtDNA copies delivered to each oocyte at 44 hr of IVM was 787.5 ± 409.3 with 44 hr deemed the most 
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appropriate time as BCB− oocytes showed large fluctuations in mtDNA copy number during the first 18 to 28 hr 
of IVM when compared to BCB+ oocytes (Supplementary Fig. 4). Indeed, supplemented mitochondria were 
tightly compact at 0 to 1 hr post-insemination and maintained their viability (Fig. 2a). At 24 hr, they were still 
present and viable within the cytoplasm and were beginning to exhibit less of a clustered feature (Fig. 2a). This 
was corroborated by transmission electron microscopy where quiescent mitochondrial morphology and dense 
organelles with translucent cristae were observed (Fig. 2b). We did find some mitochondria with more defined 
and possibly more biologically active cristae in the BCB− mISCI group at 1 hr post injection, but these mitochon-
dria where no longer detectable at 24 hr.
BCB+ oocytes inseminated by ICSI had the highest fertilisation rates (77.7%), as did BCB− oocytes, compared 
with IVF (59.9% vs 38.1%; Table 1). Blastocyst rates were not significantly different following insemination by 
IVF, ICSI and mICSI for the BCB+ group. For the BCB− group, mICSI led to significantly higher blastocyst 
rates (31.5%) compared with IVF (7.6%; P < 0.05) and improved blastocyst rates compared with ICSI (23.9%). 
Blastocyst rates for BCB− oocytes inseminated by mICSI were very similar to BCB+ blastocysts generated by ICSI 
and mICSI. Furthermore, BCB− mICSI-derived blastocysts had well-defined blastomeres with higher cell num-
bers (n = 51) than BCB+ ICSI-derived blastocysts (n = 33; Fig. 2c,d).
MtDNA replication during preimplantation development. To determine whether mtDNA was dif-
ferentially replicated during preimplantation development following each treatment, copy number was assessed 
from the 2-cell to the blastocyst stage. Although there was a slight turnover at the 4-cell stage in BCB+ IVF 
Figure 1. Mean (±SEM) mtDNA copy number in maturing and mature oocytes determined by real time 
PCR. (a) BCB+ and (b) BCB− maturing (0 hr and 22 hr) and immature (44 hr) and mature (44 hr) oocytes 
(n = 10 for each). Statistical analysis was performed using ANOVA. (c) Comparison between BCB+ and BCB− 
MII oocytes performed by t-test.
 Fertilisation
Total oocyte* 
or MII 
number % Fertilisation (total)
% Blastocyst/ 
Fert (total)
% Blastocyst/ 
Fert (±S.D)
BCB+
IVF 764* 58.4 23.7 20.6 ± 13.9
ICSI 255 77.7 34.9 33 ± 15.3
mICSI 98 62.2 31.6 31.5 ± 13.8
BCB−
IVF 507* 38.1 10.6 7.6 ± 5.8a
ICSI 136 59.9 22 23.9 ± 11.0a,b
mICSI 139 40.4 27.8 31.5 ± 15.6b
Table 1.  Development rates for BCB+ and BCB− oocytes fertilised by IVF, ICSI and mICSI. a,bDifferent 
superscripts represent significant differences, p < 0.05.
www.nature.com/scientificreports/
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Figure 2. Generation of mICSI-derived blastocysts. (a) Localization of mitochondria following injection into 
BCB− MII oocytes at 1 hr and 24 hr post insemination. Mitochondria endogenous to the oocyte are labeled with 
MitoTracker Deep Red (grey). The injected mitochondria are labeled with TMRM (red) and MitoTracker Green 
(green). The confocal z-stacks are displayed as maximum intensity projections (X40 magnification). (b) Transmission 
Electron Microscopy of MII oocytes, ICSI-1 hr, ICSI-24 hr, mICSI-1 hr, and mICSI-24 hr at 2500X, 5000X and 
25,000X magnification. Abreviations include; LD = lipid droplet, V = vacuole, M = mitochondria. (c) DAPI staining 
of ICSI BCB+ and mICSI BCB− blastocysts highlighting the presence of an inner cell mass. (d) Enlargement of a 
mICSI BCB− blastocyst.
www.nature.com/scientificreports/
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generated embryos, copy number decreased during preimplantation development (Fig. 3a, P < 0.001) until a sig-
nificant increase at the expanded blastocyst stage (Fig. 3a, P < 0.05). In BCB+ ICSI generated embryos, mtDNA 
copy number decreased at the 2-and 4-cell stages with significant expansion at the morula (Fig. 3b; P < 0.05) 
and expanded blastocyst stages (P < 0.01). For BCB+ oocytes, there was a significant turnover of mtDNA copy 
number at the 4-cell stage after IVF but not ICSI (Fig. 3e; P < 0.05). At later stages (Fig. 3e), there was signifi-
cantly higher copy number in ICSI-generated compacting morulae than from IVF (P < 0.001). The profile for the 
ICSI-derived BCB− embryos was very different to the IVF- and ICSI generated BCB+ embryos (cf. Fig. 3a–c,e).
Figure 3. MtDNA copy number for preimplantation embryos. (a) Mean (± SEM) mtDNA copy number for 
BCB+ IVF; (b) BCB+ ICSI; (c) BCB− ICSI and (d)BCB− mICSI-derived embryos determined by real time PCR 
(n = 5–10). (e) Mean (± SEM) mtDNA copy for each stage of development for embryos generated by IVF, ICSI 
and mICSI from BCB+ and BCB− oocytes.
www.nature.com/scientificreports/
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BCB− mICSI-generated embryos also exhibited very different profiles (Fig. 3d). Supplementation led to signif-
icantly higher mtDNA copy number at the 2-cell stage compared to ICSI (p < 0.01; Fig. 3d,e). This represented a 
4.4-fold increase (Table 2), whilst ICSI-generated 2 cell embryos retained only 27.8% (BCB+ ) and 50.1% (BCB−) 
of their initial mtDNA copy number. Likewise, there were significant differences in mICSI 8-cell embryos com-
pared to the other treatments (Fig. 3e). For day 7 expanded blastocysts, mtDNA copy number was > 200,000 
copies following each treatment (Fig. 3e). For mICSI BCB− blastocysts, this represented a 4.8-fold increase from 
the MII oocyte stage (Table 2) whilst for BCB+ blastocysts generated through IVF and ICSI, the increases were 
1.7-fold and 1.8-fold, respectively.
Global analysis of differential gene expression. To determine if mitochondrial transplantation mod-
ulated gene expression patterns in BCB−-derived blastocysts, global gene expression analysis was performed 
on single blastocysts generated from ICSI-BCB+ (n = 4), ICSI-BCB− (n = 3) and mICSI-BCB− (n = 4) oocytes. 
Using a linear RNA amplification protocol (Supplementary Fig. 5) and a global genome microarray, we assessed 
the expression of 28,944 probes across the different groups (Quantile normalisation, 20–100th percentile and 
detection flag filters). Principal component analysis (PCA) demonstrated the clustering of replicates to their 
respective groups, except for one mICSI-BCB− blastocyst outlier (Fig. 4a). Heat maps for gene expression also 
showed good clustering and greater similarity between the mICSI BCB− and ICSI BCB+ blastocysts than the 
ICSI BCB− blastocysts (Fig. 4b). Indeed, the probe intensities examined for genes associated with blastocyst 
development showed consistent expression of genes involved in pluripotency (Supplementary Fig. 6a), epige-
netic reprogramming (Supplementary Fig. 6b), energy metabolism (Supplementary Fig. 6c,d) and microRNAs 
(Supplementary Fig. 6e) for mICSI BCB− and ICSI BCB+ blastocysts.
Amongst each group of blastocysts, direct unpaired t-test comparisons identified several differentially 
expressed genes (DEG) (False Discovery Rate (FDR) = 0.05, Supplementary Table 2). There were 5 DEGs between 
BCB− ICSI and BCB+ ICSI blastocysts, 7 DEGs between BCB− mICSI and BCB+ ICSI blastocysts, and 1 DEG 
between BCB− mICSI and BCB− ICSI blastocysts. Across the three groups of blastocysts, ANOVA determined 
significant differences for 6 genes (FDR = 0.05, Supplementary Table 3). One DEG (predicted Ras and Rab inter-
actor 3, LOC100155709) showed a greater fold change for the mICSI-BCB− group than for the ICSI-BCB− group 
compared to ICSI-BCB+ blastocysts. However, the other 5 DEGs (the putative olfactory receptor 51H1-like 
LOC100511338, the YKT6 v-SNARE homolog LOC100513964, the uncharacterized LOC100621956 and 2 novel 
genes) had greater fold change for ICSI-BCB− than mICSI BCB− blastocysts compared to ICSI-BCB+ blastocysts.
Analysis by ANOVA without FDR (p < 0.01, absolute fold-change ((FC)) > 2) produced a total of 309 DEGs 
with significant DEGs profiled according to relative fold change between the groups. This profiling showed 
greater fold-change differences in the ICSI-BCB− blastocysts compared to ICSI-BCB+ or mICSI-BCB− blasto-
cysts (Supplementary Fig. 7a). In particular, ICSI-BCB− blastocysts had a greater number of upregulated DEGs 
with fold changes higher than 5 or 10 (Supplementary Fig. 7b), whilst mICSI-BCB− blastocysts showed a greater 
number of down-regulated DEGs (Supplementary Fig. 7c).
As large numbers of DEGs are required to reach sufficient enrichment for in silico pathway analysis, we com-
pared pairs of groups without FDR but with FC > 2 and significance of p < 0.01 (Fig. 4c; and Table 3). Using 
Ingenuity Pathway Analysis, 276/378 DEGs were annotated for the comparison between ICSI BCB− vs ICSI 
BCB+ blastocysts, which clustered into 12 networks (Supplementary Table 4). The top three networks were cel-
lular assembly and organisation; cell morphology; and amino acid metabolism. For the cellular assembly and 
organisation pathway, a large number of genes were upregulated in the ICSI BCB− blastocysts (Supplementary 
Fig. 8). Likewise, for the cell morphology (Supplementary Fig. 9) and the amino acid metabolism networks 
(Supplementary Fig. 10), a higher proportion of genes were upregulated in the ICSI BCB− blastocysts than were 
down regulated. For the canonical pathways, PPAR signaling was the most affected (Supplementary Fig. 11). Of 
the predicted upstream regulators of the DEGs, CREB1, ERB2 and BMP2 were activated, as was the pathway that 
is modulated by the anti-Type 2 Diabetes pharmaceutical agent Troglitazone (Table 4; Supplementary Table 5).
In contrast, 127/192 DEGs were annotated from the comparison between mICSI BCB− and ICSI BCB− blas-
tocysts, which clustered into seven networks (Supplementary Table 6). The cellular movement (Supplementary 
Fig. 12), cellular development (Supplementary Fig. 13) and cell morphology networks (Supplementary Fig. 14) 
ranked highest. The majority of genes in these networks were downregulated in the mICSI BCB− cohorts. The 
PPAR canonical pathway was also affected in ICSI BCB− blastocysts (Supplementary Fig. 15). Likewise, three 
predicted upstream regulators of the DEGs, namely NFKB, ILS and HRAS were significantly inhibited whilst the 
 
Oocyte 
selection and 
fertilisation
mtDNA copy number ± SEM Ratio
MII 2 cells Blastocyst 2 cells/MII Blastocyst/MII
BCB+ IVF 147063 ± 25325a 91630 ± 19950a,b 244245 ± 28765 62.3% 166.1%
BCB+ ICSI 147063 ± 25325a 40926 ± 10057a 263067 ± 45966 27.8% 178.9%
BCB− ICSI 44749 ± 10574b 22419 ± 7588a 265000 ± 33329 50.1% 592.2%
BCB+ mICSI 147063 ± 25325a nd 273712 ± 52787 nd 186.1%
BCB− mICSI 44749 ± 10574b 198539 ± 69880a 214841 ± 49107 443.7% 480.1%
Table 2.  MtDNA copy number in MII oocytes and 2-cell and blastocyst stage embryos. ANOVA between 
BCB+ and BCB− for IVF, ICSI and mICSI inseminations with different superscripts representing significant 
differences, p < 0.05.
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pathway modulated by the pharmaceutical agent resveratrol, which regulates Sirtuin activity and thus mitochon-
drial biogenesis 29, was activated (Table 4; Supplementary Table 7).
The comparison of mICSI BCB− and ICSI BCB+ blastocysts resulted in 222/311 DEGs being annotated, which 
clustered into 10 networks (Supplementary Table 8). The highest ranked of these were cell cycle, cellular compro-
mise and developmental disorders. For these networks, there was an improved balance between upregulated and 
downregulated DEGs compared to ICSI BCB− blastocysts and more DEGs showed no marked differences. Of 
the canonical pathways, the regulators of metabolism were most affected (Table 4; Supplementary Fig. 16) whilst 
MYC and STAT4 were predicted upstream regulators to be activated (Supplementary Table 9), as was the pathway 
modulating the anti-cancer pharmaceutical agent Streptozocin.
We analysed genes that were not differently expressed between ICSI-BCB+ and mICSI-BCB− but were dif-
ferently expressed in ICSI-BCB− blastocysts. 90/168 annotated genes clustered into 5 networks (Supplementary 
Table 10). The top three networks were cell morphology (Supplementary Fig. 17), gene expression and protein 
synthesis (Supplementary Fig. 18), and cell to cell signaling and interaction and cellular assembly and association 
(Supplementary Fig. 19). Glycine biosynthesis I, methylmalonyl pathway, and 2-oxobutanoate degradation I were 
the top three affected canonical pathways (Supplementary Fig. 20). However, no upstream regulators were signif-
icantly activated or inhibited (Supplementary Table 11).
Analysis of patterns of gene expression specific to embryonic development. Cohorts of blasto-
cysts (n = 5 to 10) were also analysed to determine the patterns of expression for key regulatory genes. Each of the 
pluripotent genes, OCT4 (Supplementary Fig. 21a), SOX2 (Supplementary Fig. 21b) and REX1 (Supplementary 
Fig. 21c) showed consistent levels of expression across the different groups, whilst NANOG expression was 
very low (Ct > 40) with no detection in mICSI BCB+ blastocysts (Supplementary Fig. 21d), as expected for 
porcine embryos30. The trophectodermal marker, CDX2, was consistently expressed in IVF, ICSI and mICSI 
blastocysts (Supplementary Fig. 21e). Two mtDNA-encoded genes, ND1 (Supplementary Fig. 21f) and ATP6 
(Supplementary Fig. 21g), and the nuclear-encoded mtDNA transcription factor TFAM (Supplementary Fig. 21h) 
were highly expressed and within similar range.
Discussion
The number of mtDNA copies present in developmentally competent MII oocytes is an essential investment in 
development, as embryonic cells only initiate mtDNA replication post-gastrulation20, a large number of cell divi-
sions post-fertilisation. These are important developmental events as they establish the mtDNA set point from 
Figure 4. Global gene expression analysis of single blastocysts following microarray. (a) PCA of microarray 
data from single blastocysts. Red, blue and brown points represent individual transcriptomes from ICSI BCB+ ,  
ICSI BCB− and mICSI BCB− blastocysts, respectively. (b) Heat map of global gene expression following Pearson’s  
correlation to determine hierarchical clustering between blastocysts of each group. (c) Venn diagram representing 
differentially expressed genes between ICSI BCB+ and ICSI BCB−; mICSI BCB− and ICSI BCB−; and mICSI 
BCB− and ICSI BCB+ blastocysts following unpaired t-tests, with FC > 2 (abs) and significance of p < 0.01.
www.nature.com/scientificreports/
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Top 10 differentially 
expressed genes (T-Test,  
p value < 0.01, abs. FC > 2) FC (abs) p value Regulation REFSEQ Network
Top Diseases and 
Functions
ICSI BCB− vs ICSI BCB+ blastocysts
 LOC100513964 109.53825 0.000014519855 up XM_003134882 Not displayed Undetermined
 BNP 45.177853 0.005953322 up NM_213846 Not displayed Undetermined
 NULL 34.279636 0.0000691877 up unknown Not displayed Undetermined
 ROCK2 29.54274 0.0013772815 up XM_003125386 Supp. Fig. 8 and 18
Cell Morphology, 
Cellular Assembly 
and Organization, 
Cellular Function and 
Maintenance
 LOC100518872 25.287235 0.0013035844 up XM_003133613 Not displayed Undetermined
 NULL 77.53339 0.008828815 down unknown Not displayed Undetermined
 ZNF709 33.383026 0.0010354982 down XM_003354054 Not displayed
Cellular Growth and 
Proliferation, Cell Death 
and Survival, Infectious 
Disease
 LOC100520571 21.369652 0.0006056553 down XM_003128006 Not displayed Undetermined
 ACTG2 19.070107 0.00027356512 down NM_001615.3 Not displayed
Inflammatory Disease, 
Inflammatory Response, 
Organismal Injury and 
Abnormalities
 TC2N 13.784387 0.008354094 down NM_028924.3 Supp. Fig. 9
Amino Acid Metabolism, 
Post-Translational 
Modification, Small 
Molecule Biochemistry
mICSI BCB− vs ICSI BCB− blastocysts 
 SERPINB10 50.39668 0.0082500875 up NM_005024.1 Supp. Fig. 12
Cellular Development, 
Cellular Growth 
and Proliferation, 
Hematological System 
Development and 
Function
 NULL 28.870111 0.008353462 up unknown Not displayed Undetermined
 ADAM5 19.022522 0.0037702504 up XM_003133371 Not displayed Undetermined
 NULL 16.16526 0.002920586 up unknown Not displayed Undetermined
 LOC100625749 14.306636 0.005585119 up XM_003361441 Not displayed Undetermined
 LOC100513964 98.986435 0.000018220118 down XM_003134882 Not displayed Undetermined
 NULL 50.691635 0.000014981616 down unknown Not displayed Undetermined
 IL18 37.155396 0.00052243227 down NM_001243211 Supp. Fig. 12
Cell-To-Cell Signaling 
and Interaction, Cell 
Signaling, Molecular 
Transport
 LOC100623696 36.893543 0.008665602 down XM_003356823.1 Not displayed Undetermined
 MATN3 35.507694 0.00008970674 down NM_002381 Supp. Fig. 13
Cell Morphology, 
Cellular Assembly and 
Organization, Cellular 
Development
mICSI BCB− vs ICSI BCB+ blastocysts 
 PPP1R9A 57.586193 0.00099 up NM_001166160 Not displayed
Cellular Compromise, 
Infectious Disease, Drug 
Metabolism
 NULL 56.806114 0.003806175 up unknown Not displayed Undetermined
 LOC100623901 44.763016 0.000384 up XM_003361640 Not displayed Undetermined
 LOC100526251 38.66665 0.0000941 up XM_003132878.1 Not displayed Undetermined
 LIX1L 35.739998 0.000215 up NM_153713 Not displayed Undetermined
 LOC100524253 56.918842 0.007135105 down XM_003355205 Not displayed Undetermined
 LOC100628218 41.88254 0.002997461 down XM_003354336.1 Not displayed Undetermined
 ZC3HAV1 40.911594 0.001792942 down NM_024625 Not displayed
Cellular Compromise, 
Infectious Disease, Drug 
Metabolism
 NULL 31.49758 0.005764906 down unknown Not displayed Undetermined
 NR3C1 21.502375 0.007265344 down NM_001008481.1 Not displayed
Cellular Compromise, 
Infectious Disease, Drug 
Metabolism
Table 3.  Top 10 differentially expressed genes between ICSI BCB+ and ICSI BCB−; mICSI BCB− and ICSI 
BCB−; and mICSI BCB− and ICSI BCB+ blastocysts following unpaired t-tests, with FC > 2 (abs) and 
significance of p < 0.01.
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which all naïve cells possess low numbers of mtDNA31–34. These copies of mtDNA are then replicated in a cell 
specific manner in order that mature, specialised cells acquire their specified numbers of mtDNA copy to produce 
sufficient ATP through OXPHOS to perform their specialised functions. Indeed, homozygous knockdown mice 
that are unable to initiate mtDNA replication post-gastrulation die in utero35,36.
Although ~800 copies of mtDNA were injected into mtDNA deficient oocytes, MII oocytes are receptive to 
modulating mtDNA copy number to overcome their deficiency and promote development. MtDNA deficient 
oocytes ‘hitchhike’ on an embryo’s potential to replicate mtDNA prior to the 4-cell stage, which marks embryonic 
genome activation (EGA)37. This 4.4-fold increase at the 2-cell stage following mitochondrial supplementation 
stabilises mtDNA copy number for post-EGA development and ensures that numbers are similar to IVF- and 
ICSI- derived BCB+ blastocysts. Indeed, BCB+ oocytes did not benefit from supplementation suggesting that the 
appropriate threshold had been reached. Consequently, the replication events observed in IVF and ICSI gener-
ated BCB+ embryos ensure that sufficient mtDNA is present at the blastocyst stage and are essential to continued 
embryo development.
Previously, it has been demonstrated that the supplementation of oocytes with genetically distinct populations 
of mtDNA, through cytoplasmic transfer, results in heteroplasmy22,23. In mice, the health and wellbeing of the 
offspring was compromised by a host of physiological abnormalities23. Other studies in heteroplasmic mice have 
indicated similar outcomes24. The transfer of donor cytoplasm to treat women whose embryos undergo repeti-
tive developmental arrest prior to or at EGA38–41 resulted in heteroplasmy at higher than anticipated levels even 
though the cytoplasmic extract was not a mitochondrial concentrate. Indeed, 40% of the offspring’s total mtDNA 
originated from the donor cytoplasm22,42, which supports our findings that mtDNA introduced at fertilisation 
‘hitchhikes’ on the pre-EGA mtDNA replication event to provide sufficient mtDNA investment for subsequent 
development. Nevertheless, this approach led to autism and Turner’s syndrome (XO) but not in all cases40–42.
We propose that supplementation with autologous populations of mitochondrial isolate does not perturb the 
genetic identity of the offspring but generates a stabilisation effect, which is reflected in the enhanced gene expres-
sion patterns observed at the blastocyst stage. The gene expression patterns for BCB− supplemented oocytes 
(mICSI BCB−) are far more aligned to the ICSI BCB+ cohort. The key gene networks positively affected in mICSI 
BCB− blastocysts included cellular movement, cellular development and cell morphology, which are essential to 
developmental outcomes. These networks closely resemble deficits observed in ICSI BCB− derived blastocysts 
that attempted to compensate by increasing gene expression associated with amino acid metabolism, which is 
essential to early development27.
The ‘quiet’ hypothesis suggests that early embryonic metabolism works at a quiet pace, but that insufficient 
metabolic support induces an adaptive response through increased gene expression that compromises embryonic 
development43. From the DEG profiles, it appears that BCB− ICSI blastocysts had a higher number of upregu-
lated genes compared to BCB+ ICSI blastocysts, with significant enrichment in the PPAR signaling pathway. This 
up-regulation is also predicted to involve activation of transcription factors, such as CREB1 (Table 4), an impor-
tant metabolic regulator of blastocyst development44. As CREB1 is also involved in mitochondrial maintenance 
prior to EGA45 and energy homeostasis46, it would also communicate mtDNA deficiency to BCB− embryos prior 
to EGA.
The upregulation of gene expression in BCB− derived blastocysts was stabilised by mICSI and affected PPAR 
signalling, as well as other signalling pathways such as NKkB. Notably, mICSI down-regulated genes correlated 
with upstream activation by resveratrol (Table 4). Resveratrol is an exogenous compound beneficial to oocyte 
maturation and embryo development in mice47, cattle48 and pigs29. The effects of resveratrol involves activa-
tion of Sirt1, which influences mitochondrial biogenesis as well as mtDNA copy number in porcine oocytes29. 
Consequently, the effect of mICSI on blastocyst gene expression would be to communicate via retrograde sig-
naling the stabilising effect of increased mtDNA copy number in early embryos. Collectively, these outcomes 
promote stabilised mtDNA replication under pluripotent gene control that is essential to the undifferentiated 
state, as observed in embryonic stem cells31,49,50. Likewise, the activation of MYC and STAT4 in mICSI BCB− blas-
tocysts, when compared to ICSI BCB+ blastocysts, is associated with increased cell proliferation in other cellular 
systems51, and, would account for the higher cell number observed in mICSI BCB− blastocysts.
Whilst oocyte and early embryonic mitochondria do not fully mature before the blastocyst stage, we show 
here that the mtDNA content can be modulated throughout preimplantation development, and, particularly, 
prior to embryonic genome activation. In mtDNA deficient oocytes, this modulation does not occur which could 
account for lower blastocyst development. On the other hand, the increased mtDNA copy number in BCB− 
oocytes following mICSI could counteract the homeostatic response to early mtDNA deficiency, and influence 
the embryonic development by stabilizing communication between the mitochondrial and nuclear genomes, 
which fails in other cellular systems, such as tumours, where the failure to efficiently replicate mtDNA prevents 
differentiation from taking place52. Whilst we argue that the increase in mtDNA copy number induces a stabilis-
ing effect on the embryo prior to embryonic genome activation, others have proposed that metabolic quiescence 
in oocytes and early embryos serves to protect the integrity of the mitochondrial genome53. If mitochondrial 
supplementation is to be introduced into clinical treatment, it would be pertinent to evaluate the potential for 
DNA damage by determining the levels of double strand breaks through, for example gamma H2AX labeling, or 
the comet assay, and to test for aneuploidy. This would demonstrate that there are no detrimental effects from 
supplementation on genome integrity and that, indeed, mtDNA supplementation is not inducing a metabolic 
affect that harms the embryo but, rather, supports subsequent development.
In conclusion, our outcomes demonstrate the importance of mtDNA to oocyte developmental competence, 
whereby supplementation of mtDNA deficient oocytes at fertilisation enhances embryo development and blas-
tocyst quality. It also highlights the importance of inducing early mtDNA replication events at fertilisation in 
mtDNA deficient oocytes to enhance embryo quality by stabilising the embryo prior to EGA. This mtDNA invest-
ment ensures that resultant blastocysts have increased cell numbers and enhanced gene expression profiles that 
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:23229 | DOI: 10.1038/srep23229
are associated with blastocysts from developmentally competent oocytes. We conclude that mitochondrial supple-
mentation could significantly improve fertilization and development rates in mammals. In addition to advanced 
maternal age and poor ovarian reserve, this procedure could be relevant to the rescue of in vitro matured human 
oocytes54,55, notably in women with polycystic ovary syndrome56.
Methods
All chemicals were obtained from Sigma, unless stated otherwise.
BCB staining, IVM and embryo culture. Pig ovaries, excess to the requirements of the food chain, were 
collected from a local abattoir. They were washed and maintained in PBS at 37–38 °C. Cumulus-oocyte complexes 
(COCs) were aspirated from the ovaries using a syringe with an 18G needle (Becton Dickinson) containing 
around 1 ml warm flush medium (ViGRO, Bioniche Australia). After washing in pre-equilibrated IVM medium 
consisting of TCM 199, 0.1% polyvinyl alcohol, 3.05 mM Glucose, 0.91 mM Sodium Pyruvate, 0.57 mM Cysteine, 
10 ng/mL EGF, 10 IU/mL LH (Chorulon, Intervet DE), 10 IU/mL FSH (Folligon, Intervet, DE) and 50 μg/mL 
Penicillin/streptomycin, COCs were stained with 12 μM BCB in IVM medium for 60 mins at 39 °C, 5% CO2 at 
maximum humidity. COCs were then washed in warm flush medium containing the supplements listed for IVM 
medium. BCB+ and BCB− COCs were isolated using a stereomicroscope. After sorting, COCs were plated (50 
per well) into pre-equilibrated IVM medium and incubated for 44 hours at 39 °C, 5% CO2 at maximum humidity.
After IVM, COCs underwent either IVF or ICSI followed by in vitro culture in Porcine Zygote Medium 
(PZM; saline solution containing 0.20 mM Sodium Pyruvate, 2 mM Calcium Lactate, 1 mM L-Glutamine, 5 mM 
Clustering of differentially 
expressed genes (T-Test, p 
value < 0.01, abs. FC > 2) Top Diseases and Functions Network(s)
Predicted upstream 
Regulator Molecule Type Regulation
Activation z-score 
(abs. Fold-
change > 1.5)
p-value of 
overlap 
(p < 0.05)
ICSI BCB− vs ICSI BCB+ blastocysts 
  BAG3, CCBL1, CGREF1, 
CREM, EDN1, FAM73A, 
JUN, KLF5, OXNAD1, 
PITPNB, SMN1/SMN2
Cellular Assembly and Organization, 
Cellular Function and Maintenance, 
Cell Death and Survival
Supp. Figs 7, 8, 
9, 12, 17 and 18 CREB1 transcription regulator Activation 2.617 1.57E-03
  BCAT2, EDN1, EPHX2, 
JUN, MXD3, PGK1, 
PRDX2, SMTN, SPINT1, 
UCK1
Cancer, Cellular Movement, 
Organismal Development
Supp. Figs 7, 8 
and 18 ERBB2 kinase Activation 2.236 1.51E-02
 EDN1, JUN, KLF5, SRF
Inflammatory Disease, 
Inflammatory Response, Organismal 
Injury and Abnormalities
Supp. Figs 7, 12 
and 18 lysophosphatidic acid chemical - other Activation 1.958 2.04E-03
  CALU, CELF2, CERS4, 
EPHX2, JUN, LARGE, 
LTBP1, VAV3
Cancer, Cellular Movement, 
Organismal Development Supp. Fig. 7 FOS transcription regulator Activation 1.698 3.59E-02
  AEBP1, EDN1, JUN, 
PGK1, PTPN11, 
SLC25A11
Cell Morphology, Cellular Assembly 
and Organization, Cellular Function 
and Maintenance
Supp. Figs 8 
and 18 Insulin hormone Activation 1.513 3.02E-02
  EDN1, JUN, MIOX, 
PRDX2
Cell To Cell Signaling and 
Interaction, Reproductive System 
Development and Function, Cell 
Signaling
Supp. Fig. 16 N-acetyl-L-cysteine chemical drug Inhibition − 1.941 5.0E-02
mICSI BCB− vs ICSI BCB− blastocysts 
  CCND2, EDN1, IL18, 
TRAF2
Cellular Development, Cellular 
Growth and Proliferation, 
Hematological System Development 
and Function
Supp. Figs 8, 
12, 17 and 18 Resveratrol Chemical drug Activation 1.954 1.19E-02
  CCND2, CGREF1, EDN1, 
IL18, TRAF2
Cellular Development, Cellular 
Growth and Proliferation, 
Hematological System Development 
and Function
Supp. Figs 7, 8, 
12, 17 and 18 NFkB (complex) Complex Inhibition − 2.208 3.62E-02
  CCND2, LIMK2, NABP1, 
UPB1
Cellular Movement, Hematological 
System Development and Function, 
Immune Cell Trafficking
Supp. Figs 11 
and 16 IL5 Cytokine Inhibition − 2.000 9.57E-03
mICSI BCB− vs ICSI BCB+ blastocysts
  ATF4, CLDN7, CYTH2, 
DDIT4, FTH1, LDHB, 
MCL1, SMN1/SMN2, 
TP53I3, UBE2S
Lipid Metabolism, Small Molecule 
Biochemistry, Vitamin and Mineral 
Metabolism
Not displayed MYC Transcription regulator Activation 2.156 3.13E-02
  AP2A2, ATF4, DPM3, 
LRRFIP1
Cellular Compromise, Infectious 
Disease, Drug Metabolism Supp. Fig. 7 STAT4
Transcription 
regulator Activation 2 4.01E-02
  ADIPOR2, FABP3, 
MIOX, STUB1
Carbohydrate Metabolism, Cell 
Cycle, Developmental Disorder Supp. Fig. 16 Streptozocin Chemical drug Activation 1.98 3.46E-02
Table 4.  Functional clustering of differentially expressed genes between ICSI BCB+ and ICSI BCB−; 
mICSI BCB− and ICSI BCB−; and mICSI BCB− and ICSI BCB+ blastocysts following unpaired t-tests, 
with FC > 2 (abs) and significance of p < 0.01. DEGs were clustered according to their predicted upstream 
regulators based on prior knowledge of expected regulation from the Ingenuity® Knowledge Base.
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Hypotaurine, Basal Medium Eagle and Non-essential amino-acids, 0.05 mg/ml penicillin/streptomycin and 0.3% 
BSA). For IVF, 50 COCs were plated in a 4-well plate containing pre-equilibrated mTBM solution (Tris Buffer 
Medium with 5 mM Sodium Pyruvate, 0.02 mM fresh Adenosine, 0.2 mM fresh L-Glutathione and 0.1% BSA) 
and incubated with 90% Percoll-pelleted spermatozoa (0.5 × 106) for 4 hours at 39 °C, 5% CO2 at maximum 
humidity.
For ICSI, two injection plates were prepared with a central 7 μl drop of sperm catch (Nidacon SC-100), with 
a 1 μl arm of DPBS/FBS. This was surrounded by 4, 7 μl drops of pre-equilibrated PZM and overlayed with 
pre-equilibrated mineral oil (Sage 4008). Plates were equilibrated at 38.5 °C, 5% CO2, 5% O2 for at least 1 hour. 
Sperm was added to the PBS/FBS arm and allowed to swim into the sperm catch. Immediately prior to injection, a 
single oocyte was loaded into each of the PZM drops. ICSI was performed on a Nikon TE300 inverted microscope 
with a heated stage and fitted with Eppendorf micromanipulators. Injection and holding pipettes were supplied by 
The Pipette Company, Australia. Injection pipettes had an internal diameter of 6 μm. Individual sperm that had 
migrated into the sperm catch and were motile were immobilised by scoring the tail and drawn into the injection 
pipette. The injection pipette was moved to a drop containing an oocyte. The oocyte was held with the polar body 
orientated at either 6 or 12 o’ clock. The injection pipette with the sperm in the tip was introduced into the oocyte 
at 3 o’ clock and the cytoplasm aspirated to ensure the oolemma had been ruptured before depositing the sperm. 
Post-injected oocytes were transferred to pre-equilibrated PZM for culture at 38.5 °C, 5% CO2, 5% O2. mICSI was 
performed as for ICSI except that 3 pl of mitochondrial isolate was collected into the injection pipette along with 
a single sperm and injected at the time of sperm injection.
After insemination, zygotes were cultured in PZM for 7 days at 39 °C, 5% CO2, 5% O2 at maximum humidity 
with media changes after 48 and 120 hours. Imaging of DAPI-stained nuclei in expanded blastocysts was under-
taken using a multi-photon confocal microscope (Leica TCS SP5).
Mitochondrial isolation and supplementation. Mitochondrial isolation from in vitro matured meta-
phase II BCB+ oocytes was performed using a drill-fitted Teflon pestle57. Briefly, after hyaluronidase treatment, 
mechanical stripping and multiple PBS-washes to eliminate all cumulus cells, denuded oocytes were resuspended 
in 5 mL mitochondrial isolation buffer + 2 mg/ml BSA (20 mM Hepes pH 7.6, 220 mM Mannitol, 70 mM sucrose, 
1 mM EDTA) and homogenised by no more than 10 strokes of the pestle, at 4 °C or on ice. The oocyte homogenate 
was centrifuged at 800 g for 10 minutes to remove cell debris and the supernatant was centrifuged at 10,000 g for 
20 minutes to pellet the mitochondrial fraction. The pellet was resuspended in isolation buffer without BSA then 
centrifuged at 10,000 g for 20 minutes. The supernatant was removed and the mitochondrial pellet resuspended 
in isolation buffer without BSA. The mitochondrial suspension was further concentrated by transferring it to a 
sealed straw (Flexipet, Cook Australia) followed by centrifugation for 25 seconds at 10,000 g. The mitochondrial 
suspension was dispensed onto an ICSI plate. At injection, a single sperm along with 3pl of mitochondrial isolate 
was drawn up into the injection pipette. The 3 pl of mitochondrial isolate along with the sperm was injected into 
the oocyte.
The mitochondrial isolate was quantified for mtDNA copy number by injecting an identical volume to that 
injected into oocytes into 2 μl of H2O within a PCR tube, and analysed in triplicate by real time PCR using 
mtDNA-specific primers, as described in ‘Analysis of mtDNA copy number’. Furthermore, the non-concentrated 
mitochondrial suspension (10 μl) underwent respiration analysis, as described in ‘Mitochondrial respiration 
analysis’.
Mitochondrial respiration analysis. O2 consumption rates for isolated mitochondria were determined 
by high-resolution respirometry (Oroboros Oxygraph-2K, Innsbruck, Austria). The Oxygraph was calibrated at 
0% (5% sodium hydrosulfide) and maximal (air) O2 concentration in mitochondrial respiration buffer (225 mM 
D-mannitol, 75 mM sucrose, 10 mM KCl, 10 mM Tris-HCl, 5 mM KH2PO4). After 2 minute washes of H2O, EtOH 
80%, EtOH 100% and H2O respectively, the chambers were filled with 2 ml respiration buffer maintained at 37 °C 
and continuously stirred at 750 rpm. O2 consumption was measured using the integrated software package Datlab 
(Version 3.1; Oroboros, Innsbruck, Austria), which presented respiration as O2 flux, pmol O2 per unit per sec-
ond. Following O2 flux stabilization, 25 μl of succinate (1 M) was added to the chamber as well as mitochondrial 
isolate and initial resting measurements were recorded. 10 μl of ADP (25 mM) followed by increasing doses of 
FCCP (carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone) were added at 10 minute intervals to determine 
maximal uncoupled ETC respiratory capacity. Finally, 10 μl (5 mM) of the complex III inhibitor Antimycin A was 
used to abolish respiration.
Analysis of mtDNA copy number. Individual denuded oocytes and embryos were freeze-thawed in 
50 μl of water. 2 μl was added to 10 μl SYBR green (Bioline, Australia), 6 μl of H2O and 0.5 μM of each primer. 
See Supplementary Table 12 for primer sequences, product size, annealing temperature, and accession number. 
Reactions were run in a Rotorgene-3000 (Corbett Research, Cambridge, UK), according to the following condi-
tions: 95 °C for 5 min, 45 cycles of melting temperature for 30 sec and acquisition temperature for 15 sec, followed 
by 1 cycle at ramping temperature from 72 °C to 95 °C with continuous fluorescence acquisition. All samples were 
analysed in triplicate. MtDNA copy number was extrapolated from standard curves (10-fold serial dilutions of 
2 ng target PCR product) and calculated according to the target PCR product length. To determine the number 
of mtDNA copies introduced into oocytes by mICSI, the volume of mitochondrial isolate used to supplement the 
oocytes was directly added to a PCR tube and processed and analysed, as described in ‘Mitochondrial isolation 
and supplementation’.
Imaging of mitochondria in inseminated oocytes. Denuded metaphase II oocytes were labeled 
with 100 nM MitoTracker Deep Red (Molecular Probes) in IVM medium for 45 min prior to injection. The 
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mitochondrial isolate labeled with 200 nM MitoTracker Green FM (Molecular Probes) and 20 nM TMRM 
(Molecular Probes) was centrifuged at 10,000 g for 20 minutes. The mitochondrial pellet was washed to discard 
any unbound stain and concentrated as described in ‘Mitochondrial isolation and supplementation’. Injection was 
performed as described in ‘Mitochondrial isolation and supplementation’. Presumptive embryos were transferred 
into 8-well chamber slides on a coverslip (Sarstedt, product no. 94.6190.802).
Brightfield and MitoTracker Deep red images of presumptive embryos and fluorescent images of injected 
mitochondria were recorded on a Nikon C1 confocal microscope using a 40X oil immersion objective. 488 nm, 
561 nm, and 639 nm lasers were used to specifically excite MitoTracker Green, TMRM and MitoTracker Deep Red 
in a sequential manner. Confocal z-stacks of 50 μm thickness with 5 μm increments between slices were recorded 
of the lower half of each oocyte.
Shape Analysis of Mitochondrial Clusters. Oocytes were stained with 100 nM MitoTracker Deep Red 
(Molecular Probes) for 45 min and then transferred into 8-well chamber slides on a coverslip (Sarstedt, product 
no. 94.6190.802). Images of MitoTracker Deep Red were recorded on a Nikon C1 confocal microscope using a 40x 
oil immersion objective. Confocal z-stacks of 50 μm thickness with 5 μm increments between slices were recorded 
of the lower half of each oocyte.
Image processing and analysis was performed using Fiji software. For shape analysis of mitochondrial clusters, 
a suitable region of interest (ROI) with even staining of mitochondria and excluding any oocyte edges was chosen 
for each data set. The ROIs were then thresholded and binarized. Particle analysis was then performed to detect 
and characterize clusters. Cluster area, perimeter and circularity were chosen as parameters for characterization. 
Clusters at ROI edges were excluded from the analysis. A total of 7 BCB− and 9 BCB+ oocytes and 402 and 651 
mitochondrial clusters, respectively, were analyzed.
Imaging of blastocysts to assess cell number. Day 7 blastocysts derived from ICSI BCB+ and mICSI 
BCB− oocytes were fixed using 4% paraformaldehyde, then permeabilized in 1% TRITON X-100 and stained 
with DAPI. Image capture of DAPI stained blastocysts was performed by confocal microscopy using the multi-
photon Leica SP8 (Leica Microsystems, Ontario Canada). Cell number represents the number of DAPI-stained 
nuclei per blastocyst.
Transmission Electron Microscopy. Porcine eggs were fixed for at least 48 hours at MII, 1 hr and 24 hr 
post-ICSI and/or post-mICSI in freshly made 2% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M sodium 
cacodylate buffer. Samples then underwent osmication and uranyl acetate staining, dehydration in alcohols and 
embedded in Taab 812 Resin (Marivac Ltd., Nova Scotia, Canada). Subsequent blocks were cut and sectioned 
with a Leica ultracut microtome, picked up on 100 mesh formvar/carbon coated Cu grids, stained with 0.2% lead 
citrate, and imaged under the Phillips Technai BioTwin Spirt electron microscope.
RNA extraction, amplification and reverse transcription. RNA was extracted from single or pooled 
blastocysts using the Picopure RNA isolation Kit (Arcturus), according to the manufacturer’s instructions. 
Extracted RNA was treated with DNAse I to remove genomic DNA. RNA was amplified by 2 rounds of in vitro 
transcription (Arcturus RiboAmp HS PLUS, Life Technologies) or reverse-transcribed (random primers) using 
Superscript III (Life Technologies), according to the manufacturer’s instructions. After reverse-transcription, 
cDNA was diluted in 50 μl H2O and real time PCR was conducted using a Rotorgene-3000. Relative differences 
in Ct values were compared to IVF BCB+ blastocysts and normalized against ß-Actin (ACTB). Primer sequences, 
product size, annealing temperature, and accession numbers are provided in Supplementary Table 12.
Microarray analysis. Highly diluted RNA Spike-Ins (Agilent #5188-5279, CA) were added at the time of 
RNA extraction to individual blastocysts58,59. Quality and concentration of extracted RNA were analyzed before 
and after T7 RNA amplification (Bio analyzer, Agilent). 1.8 μg amplified RNA was labeled with Cy3-ULS using 
the Agilent DNA ULS Fluorescent Labeling kit. The Degree of Labeling (DOL) was measured with the Nanodrop 
ND-1000 Spectrophotometer (Thermo Scientific). 1.65 μg of Cy3 labeled antisense RNA (aRNA; DOL 1–3.5%) 
was fragmented at 60 °C for 30 minutes in a reaction volume of 25 μl containing 1x Agilent fragmentation buffer 
and 4.4x Agilent blocking agent, according to the manufacturer’s instructions. On completion, 55 μl of 2x Agilent 
gene expression hybridisation buffer, 3 μl H2O and 27 μl CGH ULS block were added and 100 μl of the mixture 
was hybridised for 17 hours at 67 °C in a rotating Agilent hybridisation oven. After hybridisation, EmbryoGENE 
Porcine − 4 X 44K (ID 031068) microarrays (Agilent Technologies, CA) were washed for 1 minute at room tem-
perature with GE wash buffer 1 (Agilent) and 1 minute with 37 °C GE wash buffer 2 (Agilent, CA). Slides were 
scanned immediately after washing on the Agilent C DNA microarray scanner. The scanned images were analyzed 
using Feature Extraction Software 11.0.1.1 (Agilent). Ingenuity pathway analysis (IPA) was used to determine the 
signaling pathways underlying the transcriptomic differences (p < 0.05, abs. FC > 2) between blastocysts derived 
from ICSI BCB+ , ICSI BCB− and mICSI BCB− oocytes. Lists of DEGs from each direct comparison were pre-
pared and imported into IPA by uploading lists of DEGs into separate experiments.
Gene expression analysis in IPA. DEGs were matched with their universal gene symbols, then compiled 
into canonical pathways as well as gene product interactions (networks) that are developed from information con-
tained in Ingenuity’s Knowledge Base. Canonical pathway analysis identified the pathways from the IPA library 
of canonical pathways that were most significant to the data set (enrichment score and probability). Networks of 
network-eligible molecules were algorithmically generated based on their connectivity. Green and red symbols 
represented genes respectively down-and up-regulated. DEGs were also submitted to upstream regulator analysis, 
which is based on prior knowledge of expected effects between transcriptional regulators and their target genes 
stored in the Ingenuity® Knowledge Base. The analysis examines how many known targets of each transcription 
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regulator are present in the dataset, and also compares their direction of change (i.e. expression in the experi-
mental sample(s) relative to control) to what is expected from the literature in order to predict likely relevant 
transcriptional regulators. Each potential transcriptional regulator is given a p-value (probability to overlap with 
the data set) and an activation score (likelihood to be activated or inhibited with regard to the expression of target 
genes).
Statistics. An unpaired t-test was used to compare mtDNA copy number between MII BCB+ and BCB− 
oocytes and lysis rates. Direct comparison of global gene expression from microarray analysis was performed 
using an unpaired t-test corrected for false discovery rate (FDR) or filtered for absolute (abs.) fold-change >2 
and p-value < 0.01. One-way ANOVA was used to compare MII rates and lysis rates; blastocyst rates; mtDNA 
replication profiles during either IVM, preimplantation development or between BCB staining/treatments; and 
differential gene expression in BCB blastocysts generated by ICSI or mICSI. ANOVA results for differential gene 
expression were corrected for FDR. Using Agilent’s GeneSpring GX software, microarray data for each single blas-
tocyst were subjected to principal component analysis and global gene expression was clustered by hierarchical 
Pearson’s correlation. Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity) 
was used to determine significant enrichment of biological pathways associated with differentially expressed 
genes. Statistical significance is represented as *, **, ***, **** for p values of < 0.05, 0.01, 0.001, 0.0001, respectively.
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